Senti Biosciences, Inc. operates as a clinical-stage biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (“NK”) cells to create CAR-NK cells outfitted with gene circuit technologies in several oncology indications with high unmet need. The company product candidates include SENTI-202, is a potentially first-in-class Logic Gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers, relapsed/refractory hematological malignancies, including Acute Myeloid Leukemia (“AML”); and SENTI-301A, is a multi-armed, off-the-shelf CAR-NK cell therapy for the treatment of solid tumors, and hepatocellular carcinoma (“HCC”). In addition, it develops the Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.